OARSI 2016: Chondroitin sulfate reduces cartilage volume loss vs. celecoxib in knee OA .
In a two-year double-blind randomized controlled multicenter study, chondroitin sulfate was significantly superior to celecoxib at reducing cartilage loss with similar efficacy at reducing disease symptoms in knee osteoarthritis patients
194 patients with knee osteoarthritis were randomized to undergo treatment once a day for 24 months with either 1200mg chondroitin sulfate or 200mg celecoxib. The study was conducted in order to investigate suggestions in prior studies that chondroitin sulfate provides benefits in preserving the integrity of cartilage and slowing its progressive deterioration. The findings of this study displayed significantly reduced cartilage volume loss in the chondroitin sulfate group in the medial tibiofemoral compartment and global knee at 12 months and in the medial tibiofemoral compartment at 24 months. Changes in synovial thickness, bone marrow lesion size, joint swelling and effusion, and clinical outcomes were comparable between groups, as were the occurrence of adverse events.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
